This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2026 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.86% per year. These returns cover a period from January 1, 1988 through February 2, 2026. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View the Zacks #1 Rank List
Zacks News
Leveraged ETF: How to Use & What's Hot Now?
by Neena Mishra
Geared funds are complex products; here is what you should know.
3 Oil ETFs to Ride the Crude Rally
by Neena Mishra
We highlight 3 popular ETFs that track oil prices using futures
Oil in Backwardation: 7 ETFs That Topped the Chart Last Week
by Sanghamitra Saha
Crude oil prices increased to a more than seven-year high on Jan 28 and reported six straight weeks of gains.
5 Leveraged Energy ETFs to Play Geopolitical Tensions in Gulf
by Sanghamitra Saha
Leveraged energy ETFs are likely to be intriguing plays currently as United Arab Emirates has vowed to retaliate against Houthi militants for the attack that set off explosions in fuel trucks, causing a fire near the airport in Abu Dhabi.
Profit From Higher Oil Price With These Leveraged ETFs
by Sweta Killa
Many investors have turned bullish on the energy sector and are seeking to tap this opportunity. For them, a leveraged play on energy ETFs could be an excellent idea.
5 Best Inverse/Leveraged ETF Areas of Last Week
by Sanghamitra Saha
Wall Street was moderately upbeat last week with the S&P 500, the Dow Jones and the Nasdaq Composite gaining moderately.
6 Top-Performing Leveraged/Inverse ETFs of September
by Sweta Killa
September proved the historical trends to be true as Wall Street logged in the worst month of this year.
The Zacks Analyst Blog Highlights: DIG, ERX, GUSH and NRGU
by Zacks Equity Research
The Zacks Analyst Blog Highlights: DIG, ERX, GUSH and NRGU
Play the Rising Energy Sector With These Leveraged ETFs
by Sweta Killa
Amid the strong optimism and rising oil price, the energy sector looks attractive. Many investors have turned bullish on the energy sector and are seeking to tap this opportunity.
7 Best Leveraged ETF Areas of Last Week
by Sanghamitra Saha
Wall Street was upbeat last week. News of zero new cases in China, U.S. FDA's full approval of Pfizer-BioNTech Covid-19 vaccine and no new flare-up in taper talks led to the gains.